If you are guiding an advanced cancer patient who has exhausted all effective treatment options, consider recommending they join this new clinical study. This study might offer them a completely new set of treatments, along with test results indicating which of these new treatments are most likely to be effective.
The benefits this clinical study can offer your patient include:
- Access to FDA-approved off-guideline cancer drugs, proven to be safe and effective for other cancer patients.
- Personalized selection of treatments based on diagnostic tests that identify which off-guideline drugs are likely to be most effective.
- Available to virtually every cancer patient with a qualifying diagnostic test, with no travel required: the patient receives treatment from their oncologist at their usual cancer hospital.
Background
Cancer Commons has launched a clinical study (CCCS001 on www.clinicaltrials.gov) that enables advanced cancer patients who have exhausted effective treatments to access FDA-approved off-guideline drugs that are currently unavailable to them under the NCCN Guidelines.
Off-guideline drugs are FDA-approved cancer medications that are approved for certain types of cancer but not specifically for the patient's cancer type. For each type of cancer, the number of off-guideline drugs significantly surpasses the number of on-guideline drugs, offering a vast and untapped array of new treatment options for advanced cancer patients who have no remaining effective treatments.
To participate in the study, a patient must meet three requirements: (1) they must have a diagnostic test (genomic or DST) indicating that one or more off-guideline drugs might be effective for them, (2) they must have an oncologist willing to administer FDA-approved off-guideline drugs, and (3) they must be able to access the off-guideline drugs, either through their insurance or another method.
The study does not have designated sites. As the treating oncologist, you can administer treatment to the patient at your current hospital.
For more information, please visit www.cancercommons.org/CCCS001
